Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2025)

Historic Net Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 105.81%.

  • Rhythm Pharmaceuticals' Net Margin rose 294300.0% to 105.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 113.41%, marking a year-over-year increase of 1190100.0%. This contributed to the annual value of 203.32% for FY2024, which is 352000.0% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Net Margin is 105.81%, which was up 294300.0% from 98.93% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Net Margin's 5-year high stood at 125000.0% during Q1 2021, with a 5-year trough of 12915.69% in Q2 2021.
  • Moreover, its 5-year median value for Net Margin was 242.98% (2023), whereas its average is 5163.35%.
  • Over the last 5 years, Rhythm Pharmaceuticals' Net Margin had its largest YoY gain of 124207900bps in 2022, and its largest YoY loss of -1285067400bps in 2022.
  • Rhythm Pharmaceuticals' Net Margin (Quarter) stood at 2798.84% in 2021, then surged by 83bps to 483.42% in 2022, then soared by 64bps to 171.8% in 2023, then surged by 38bps to 106.7% in 2024, then increased by 1bps to 105.81% in 2025.
  • Its last three reported values are 105.81% in Q3 2025, 98.93% for Q2 2025, and 155.39% during Q1 2025.